Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5052W HIGH $1.39
Volume
15.92 K
Value Traded
26.34 K
Short % Float
0.02%
+6.95%Week
+4.09%1 Month
-13.52%3 Month
-26.3%6 Month
-90.21%5 Year
-93.3%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
36.69 M
EPS (TTM)
1.17
P/E Ratio
0.71
Ent. Value
16.80 M
Total Shares
44.29 M
Float Shares
35.35 M
Insiders
20.19%
Institutions
26.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ELUT Catalyst Timeline
Dated clinical, regulatory and corporate events for Elutia, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Elutia, Inc.
197Total events
14Upcoming
45Tier-1 (high impact)
2020 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Milestone PaymentCorporate
Elutia receives full $8M escrow holdback from Boston Scientific BioEnvelope sale
▲AcquiredSimpliDermCorporate
Cellution Biologics completes acquisition of SimpliDerm from Elutia
▲Debt Royalty FinancingCorporate
Elutia secures $15 million loan financing from Avenue Capital Group
▲Manufacturing MilestoneCMC / Inspection
Installation and operational qualification of automated drug-coating system completed
▲RWE DataNXT-41xClinical Data
Independent blinded survey of 50 plastic and reconstructive surgeons reported
plastic and reconstructive surgerysource ↗
◆AcquisitionCorporate
Cellution Biologics signs definitive agreement to acquire SimpliDerm business from Elutia
▲Partnership / LicenseSimpliDermCorporate
Elutia signs definitive agreement to sell SimpliDerm to Cellution Biologics for up to $11M
human acellular dermal matrixsource ↗
▲Milestone PaymentSimpliDermCorporate
Up to $3M in milestone payments over 18 months post-closing
◆FDA Filing AcceptedNXT-41FiledRegulatory Filing
FDA clearance for NXT-41 base matrix
breast reconstructionsource ↗
◆Oral PresentationPresentation
Elutia to present at Planet MicroCap Showcase 2026
post-surgical infection in implant-based breast reconstructionsource ↗
◆Timing GuidanceNXT-41FiledPresentation
Anticipated FDA clearance for NXT-41
breast reconstructionsource ↗
◆Product LaunchNXT-41FiledPost-Market
Initial product launch of NXT-41 platform for breast reconstruction
breast reconstructionsource ↗
◆FDA Feedback ReceivedNXT-41FiledFDA Meeting
FDA clearance of base matrix for NXT-41 platform
breast reconstructionsource ↗
▲Manufacturing MilestoneNXT-41xCMC / Inspection
New automated manufacturing process brought online for NXT-41x
◆Oral PresentationPresentation
Elutia management presentation at Sidoti Small-Cap Virtual Investor Conference
post-surgical infection in implant-based breast reconstructionsource ↗
◆Oral PresentationNXT-41xPresentation
Elutia to present NXT-41x program at Global BioInnovation Forum
plastic and reconstructive surgerysource ↗
◆NDA SubmissionNXT-41FiledRegulatory Filing
FDA filing submission for NXT-41 base matrix
breast reconstructionsource ↗
▲Equity OfferingCorporate
Strengthened financial position: $26.9M debt eliminated, $44.3M cash and escrowed proceeds
▲AcquisitionBioEnvelopeCorporate
Closed $88 million sale of BioEnvelope business to Boston Scientific Corporation
◆Pipeline PrioritizationNXT-41xCorporate
Rapidly advancing NXT-41x for plastic and reconstructive surgery
plastic and reconstructive surgerysource ↗
▲AcquisitionCorporate
Closing of BioEnvelope business sale to Boston Scientific for $88 million
▲Partnership / LicenseCorporate
Closing of $88 million sale of BioEnvelope business to Boston Scientific
◆Oral PresentationEluProApprovedPresentation
EluPro selected to exhibit at Vizient Innovative Technology Exchange
cardiac implantable electronic devices (CIEDs) and neurostimulatorssource ↗
▲Full ResultsClinical Data
Publication of clinical and preclinical data for biologic envelope in Frontiers in Cardiovascular Medicine
cardiac implantable electronic device (CIED) pocket managementsource ↗
◆Oral PresentationPresentation
Lake Street Capital Markets 9th Annual Best Ideas Growth Conference 1x1 Meetings
◆Oral PresentationPresentation
Elutia management presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Partnership / LicenseEluProApprovedCorporate
Strategic distribution partnership with Boston Scientific
cardiac implantable electronic device proceduressource ↗
▲PublicationEluProApprovedPresentation
Publication of validated method for measuring antibiotic release from EluPro
antibiotic-eluting bioenvelope for cardiac implantable electronic devices and neurostimulatorssource ↗
▲Partnership / LicenseEluProApprovedCorporate
Boston Scientific distribution partnership now underway
cardiac implantable electronic devicesource ↗
▲Product LaunchPost-Market
Elutia commences direct sales of cardiovascular portfolio after transition from LeMaitre
cardiovascularsource ↗
◆Oral PresentationPresentation
Elutia participation in Chardan's Trending Issues in Drug Development Conference Series
Past FDA Catalysts and PDUFA Decisions
How ELUT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ELUT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| antibiotic-eluting biologic envelopes | management of cardiac implantable electronic devices (CIEDs) | 2025-09-16 | overall procedural difficulty reduction: 43%; easier generator mobilization: 46%; easier lead mobilization: 41%Read More | Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of ReoperationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Williams Michelle LeRouxOfficer (CHIEF SCIENTIFIC OFFICER) | Option | 12,500 130,552 held | $0.00 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELUT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ELUT for Q2 2026. | ||||
ELUT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELUT ranks across every disease it competes in
Competitive Position is a premium feature
See how ELUT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELUT News
ELUTElutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia Inc. has successfully received an $8 million payment from Boston Scientific, concluding its escrow holdback period. This payment, part of a larger $88 million transaction, ensures that Elutia is fully funded through the anticipated NXT-41x launch and into 2029. The company has met all its funding milestones for 2026, reinforcing its financial stability as it prepares for regulatory approval of NXT-41x in 2027.
Read more →ELUTElutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Elutia Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15-16, 2026. CEO Dr. Randy Mills, CSO Dr. Michelle Williams, and CFO Matthew Ferguson will discuss their drug-eluting biomatrix technology aimed at reducing post-surgical infections in plastic surgeries. The presentation will be accessible live and will replace a previously scheduled pre-recorded session.
Read more →ELUTElutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Elutia Inc. will participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Key executives will engage in one-on-one meetings with investors and present their innovative drug-eluting biomatrix technology aimed at addressing post-surgical infections. The conferences are scheduled for September 10 and September 15-16, 2026.
Read more →ELUTCellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
Cellution Biologics has completed the acquisition of SimpliDerm from Elutia Inc., marking its entry into the U.S. reconstructive surgery market. This acquisition enhances Cellution's portfolio by adding an established human acellular dermal matrix product. The deal, valued at $8 million with potential additional payments, aims to leverage Cellution's expertise in tissue processing and manufacturing.
Read more →ELUT▼ -6.8%on this newsshared move
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Elutia Inc. has completed the sale of its SimpliDerm business to Cellution Biologics for up to $11 million, including $8 million at closing. This divestiture allows Elutia to concentrate on its NXT-41x product, aimed at reducing post-operative infections in plastic surgery. The company anticipates FDA clearance for NXT-41x in early 2027.
Read more →ELUT▲ +9.4%on this newsshared move
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Elutia Inc. has secured up to $26 million to support the launch of its NXT-41x product, which aims to address infection risks in surgical procedures. A recent survey indicates strong interest from surgeons, with FDA clearance expected for NXT-41 in late 2026 and NXT-41x in early 2027. Despite this positive outlook, the company reported a decrease in net sales and significant operating losses.
Read more →ELUT▲ +9.4%on this newsshared move
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
Elutia has secured a $15 million loan from Avenue Capital Group to support the launch of its NXT-41x product. The financing includes an initial $10 million, with an additional $5 million contingent on FDA 510(k) clearance. This funding strategy aims to enhance shareholder value while targeting the growing market for antibiotic-eluting biomatrix in plastic and reconstructive surgery.
Read more →ELUT▼ -5.3%on this news
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Elutia Inc. will announce its second quarter 2026 financial results on August 13, 2026. The company will host a conference call and webcast at 5:00 p.m. ET to discuss these results. Interested parties can register for the call and access the webcast via the company's investor relations page.
Read more →ELUTCellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio
Cellution Biologics Inc. has signed a definitive agreement to acquire the SimpliDerm human acellular dermal matrix business from Elutia Inc. for $8 million, with potential additional payments. This acquisition marks Cellution's entry into the U.S. reconstructive surgery market and expands its biologics portfolio. The company aims to ensure a seamless transition and maintain product supply for existing customers.
Read more →ELUTElutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia Inc. has signed a definitive agreement to sell its SimpliDerm® business to Cellution Biologics for up to $11 million. The deal includes $8 million in cash at closing and up to $3 million in milestone payments over 18 months. This divestiture allows Elutia to concentrate resources on NXT-41x, a next-generation biomatrix aimed at the plastic and reconstructive surgery market, with a commercial launch anticipated in 2027.
Read more →ELUT▼ -8%on this news
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
Elutia Inc. will present at the Planet MicroCap Showcase 2026 on June 17-18, 2026, in Las Vegas. CEO Dr. Randy Mills and CSO Dr. Michelle Williams will discuss their innovative drug-eluting biomatrix technology aimed at reducing post-surgical infections in breast reconstruction. The event includes one-on-one meetings with investors, emphasizing Elutia's commitment to improving patient outcomes.
Read more →ELUT▲ +6.8%on this news
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia Inc. has announced the granting of equity awards under the 2026 Inducement Award Plan, with 48,000 non-qualified stock options issued to a new employee. The options vest over four years and were granted at the Nasdaq closing price of $1.05 per share. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Elutia's commitment to compliance and growth in the burgeoning field of drug-eluting biomatrix technologies.
Read more →ELUTElutia to Present at the 16th Annual LD Micro Invitational on May 18th
Elutia Inc. will present at the 16th Annual LD Micro Invitational on May 18, 2026. CEO Dr. Randy Mills and CFO Matt Ferguson will discuss their innovative drug-eluting biomatrix technology aimed at reducing post-surgical infections in breast reconstruction. The presentation will highlight the company's commitment to improving patient outcomes in this area.
Read more →ELUTElutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
Elutia Inc. reported its first quarter 2026 results, highlighting progress on NXT-41x, an antibiotic-eluting product aimed at the reconstructive surgery market. The FDA review for NXT-41 is advancing, with anticipated clearance in late 2026. The company has also implemented a new automated manufacturing process aimed at achieving gross margins above 80%. Despite these advancements, Elutia reported a net loss of $7.9 million for the quarter.
Read more →ELUTElutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Elutia Inc. has announced it will release its first quarter financial results for 2026 on May 14, 2026. The company will host a conference call and webcast to discuss these results, aimed at keeping investors informed. With an emphasis on drug-eluting biomatrix technologies, Elutia seeks to enhance patient compatibility with medical devices, reflecting its mission to humanize medicine.
Read more →ELUTElutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19
Elutia Inc. will present at the Sidoti Small-Cap Virtual Investor Conference on March 18-19, 2026. The CEO and CFO will discuss the company’s efforts in addressing post-surgical infections in implant-based breast reconstruction, a critical area for patient recovery. This presentation aims to inform investors about the potential impact of Elutia's drug-eluting biomatrix technology, designed to enhance surgical outcomes. The event highlights Elutia's commitment to improving patient care in the field of reconstructive medicine.
Read more →ELUTElutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
Elutia Inc. has reported its fourth quarter and full year 2025 financial results, highlighting a successful submission of its base biologic matrix, NXT-41, to the FDA and anticipating its clearance by late 2026. The company generated $44.4 million in cash at year-end, following the divestiture of the BioEnvelope business to Boston Scientific, which has allowed Elutia to eliminate debt and refocus on its core operations. CEO Dr. Randy Mills expressed confidence in the company's prospects and its mission to improve outcomes in breast reconstruction procedures.
Read more →ELUTElutia Regains Compliance with Nasdaq Listing Requirements
Elutia Inc. has announced that it has regained compliance with Nasdaq's listing requirements, specifically regarding minimum bid price and market value. The company’s Class A common stock will continue to be listed on the Nasdaq Capital Market. CFO Matt Ferguson expressed optimism about the increase in share price, attributing it to investor confidence in their drug-eluting biomatrix technology.
Read more →ELUTElutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
Elutia Inc. has appointed Pete Ligotti as Chief Commercial Officer to spearhead the launch of NXT-41x, a next-generation antibiotic-eluting biomatrix aimed at improving outcomes in breast reconstruction surgery. With over 162,000 procedures performed annually in the U.S., the company sees a significant market opportunity. NXT-41x is expected to receive FDA clearance in 2027, addressing persistent infection rates in existing surgical practices.
Read more →About Elutia, Inc.
Headquarters12510 PROSPERITY DRIVE, SILVER SPRING, MD, 20904
BIOPHARMAWATCH ELITE PLUS
Trade the next ELUT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime